Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Matei

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Oncogene|June 24, 2014
β-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroidsS Condello, C A Morgan, S Nagdas, et al.
Physical Review Letters|March 10, 2012
Formation of Ge nanoripples on vicinal Si (1110): from Stranski-Krastanow seeds to a perfectly faceted wetting layerG Chen, B Sanduijav, D Matei, et al.
Cancer Investigation|October 13, 1999
Actual 5-year survival of patients with stage IIIB breast carcinoma: phase II trial of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acidS Madajewicz, D Matei, P Hentschel, et al.
Ftiziologia|January 1, 1971
[Research on the possibilities of transporting sputum for cultures of Mycobacterium tuberculosis]P Mihăilescu, V Bogdănescu, S Teodoru, et al.
Oncogene|December 7, 2005
Autocrine activation of PDGFRalpha promotes the progression of ovarian cancerD Matei, R E Emerson, Y-C Lai, et al.
Cancer|October 15, 1995
Preclinical and clinical evaluation of 5-fluorouracil biochemical modulation with folinic acid and hydroxyurea for patients with colorectal carcinomaD Matei, N Hagag, S Madajewicz, et al.
Oncogene|April 5, 2016
NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancerA R Özeş, D F Miller, O N Özeş, et al.
Gynecologic Oncology|September 30, 2011
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology GroupR Ramasubbaiah, S M Perkins, J Schilder, et al.
Oncogene|August 13, 2013
Epithelial ovarian cancer experimental modelsE Lengyel, J E Burdette, H A Kenny, et al.
European Journal of Cancer (Oxford, England : 1990)|June 12, 2009
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancerI Vergote, N Finkler, J del Campo, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Oncogene|June 24, 2014
β-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroidsS Condello, C A Morgan, S Nagdas, et al.
Physical Review Letters|March 10, 2012
Formation of Ge nanoripples on vicinal Si (1110): from Stranski-Krastanow seeds to a perfectly faceted wetting layerG Chen, B Sanduijav, D Matei, et al.
Cancer Investigation|October 13, 1999
Actual 5-year survival of patients with stage IIIB breast carcinoma: phase II trial of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acidS Madajewicz, D Matei, P Hentschel, et al.
Ftiziologia|January 1, 1971
[Research on the possibilities of transporting sputum for cultures of Mycobacterium tuberculosis]P Mihăilescu, V Bogdănescu, S Teodoru, et al.
Oncogene|December 7, 2005
Autocrine activation of PDGFRalpha promotes the progression of ovarian cancerD Matei, R E Emerson, Y-C Lai, et al.
Cancer|October 15, 1995
Preclinical and clinical evaluation of 5-fluorouracil biochemical modulation with folinic acid and hydroxyurea for patients with colorectal carcinomaD Matei, N Hagag, S Madajewicz, et al.
Oncogene|April 5, 2016
NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancerA R Özeş, D F Miller, O N Özeş, et al.
Gynecologic Oncology|September 30, 2011
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology GroupR Ramasubbaiah, S M Perkins, J Schilder, et al.
Oncogene|August 13, 2013
Epithelial ovarian cancer experimental modelsE Lengyel, J E Burdette, H A Kenny, et al.
European Journal of Cancer (Oxford, England : 1990)|June 12, 2009
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancerI Vergote, N Finkler, J del Campo, et al.
Pageof 4